> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Low-dose rivaroxaban and mortality in coronary artery disease, pooled from five trials
- URL: https://www.coios.me/low-dose-rivaroxaban-and-mortality-in-coronary-artery/
- Published: 2026-11-22T12:58:59.000Z
- Updated: 2026-11-22T13:55:04.000Z
- Description: Across five randomised trials in coronary artery disease, low-dose rivaroxaban was linked to lower all-cause mortality than standard antithrombotic therapy.
- Author: Daniel Ryan
- Tags: Health today, Heart and stroke, World, #peer-reviewed, #confirms, #item, #source-2026-11, #score-58

This meta-analysis compared low-dose rivaroxaban with standard antithrombotic therapy across the spectrum of coronary artery disease. It pooled five randomised controlled trials, with 37 709 patients, found through MEDLINE, EMBASE, Cochrane and meeting proceedings. All-cause mortality was lower with rivaroxaban (incidence rate ratio \[IRR\] 0.83, 95% CI 0.70-0.98), driven by cardiovascular mortality (IRR 0.82). Myocardial infarction (IRR 0.88) and stroke (IRR 0.71) were also reduced. Ischaemic stroke was also lower (IRR 0.60), with no offsetting rise in haemorrhagic stroke. Major bleeding rose (IRR 1.46), though its interval of 0.99-2.17 included no effect, and fatal bleeding did not rise.

*Why it is interesting: The pooled trials show a fall in deaths, not only in heart attacks and strokes. That fall in deaths came with more major bleeding, though fatal bleeding did not rise.*

Source

[Journal of Invasive Cardiology, 20 November 2026](https://doi.org/10.25270/jic/26.00286?ref=coios.me)

Paper

Reduced mortality with low-dose rivaroxaban in patients with coronary artery disease: a meta-analysis

Authors

Palmerini T, Nardi E, Lezzi M, Bruno AG, Lombardi L, Chi G et al.

DOI

10.25270/jic/26.00286

Type

Peer-reviewed article

Design

Meta-analysis of 5 randomised controlled trials, 37,709 patients, low-dose rivaroxaban vs standard antithrombotic therapy in coronary artery disease

Verdict

Confirms prior evidence

Driver

[Heart and stroke](https://www.coios.me/d-cardiovascular/)